Checkpoint Therapeutics, Inc. Stock
Checkpoint Therapeutics, Inc. Stock price
Key metrics
| Market capitalization | $370.71m |
| Enterprise Value | $337.67m |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 21.90 |
| Free Cash Flow (TTM) Free Cash Flow | $-36.31m |
| Cash position | $33.04m |
| P/E forward | negative |
| P/S forward | 9.02 |
| EV/Sales forward | 8.21 |
Is Checkpoint Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Checkpoint Therapeutics, Inc. Stock Analysis
Analyst Opinions
3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:
Analyst Opinions
3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:
Financial data from Checkpoint Therapeutics, Inc.
| Dec '24 |
+/-
%
|
||
| Revenue | 0.04 0.04 |
64%
64%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -56 -56 |
8%
8%
|
| Net Profit | -56 -56 |
8%
8%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Checkpoint Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Checkpoint Therapeutics, Inc. Stock News
Company Profile
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
| Head office | United States |
| CEO | James Oliviero |
| Employees | 24 |
| Founded | 2014 |
| Website | checkpointtx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
